Incorporating data received after a sequential trial has stopped into the final analysis : implementation and comparison of methods

dc.contributor.authorSooriyarachchi, M.R.
dc.contributor.authorWhitehead, J.
dc.contributor.authorBolland, K.M.
dc.contributor.authorWhitehead, A.
dc.contributor.authorMatushita, T.
dc.date.accessioned2021-07-07T03:29:14Z
dc.date.available2021-07-07T03:29:14Z
dc.date.issued2003
dc.description.abstractIn a sequential clinical trial, accrual of data on patients often continues after the stopping criterion for the study has been met. This is termed “overrunning.”Ov errunning occurs mainly when the primary response from each patient is measured after some extended observation period. The objective of this article is to compare two methods of allowing for overrunning. In particular, simulation studies are reported that assess the two procedures in terms of how well they maintain the intended type I error rate. The effect on power resulting from the incorporation of “overrunning data”using the two procedures is evaluateden_US
dc.description.sponsorshipWelcome Trusten_US
dc.identifier.citation.Sooriyarachchi, M.R., Whitehead, J. Bolland, K., Whitehead, A., Matsushita, T. Incorporating data received after a sequential trial has stopped into the final analysis : implementation and comparison of methods, Biometrics 59, 701-709, 2003en_US
dc.identifier.urihttp://archive.cmb.ac.lk:8080/xmlui/handle/70130/5488
dc.language.isoenen_US
dc.publisherWiley Blackwellen_US
dc.subjectClinical trials; Delayed data; Interim analysis; Overrunning; P-value function; Sequential methodsen_US
dc.titleIncorporating data received after a sequential trial has stopped into the final analysis : implementation and comparison of methodsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
biom-[701-709][2].pdf
Size:
109.08 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: